Physician profile
Eva Y Ramirez
NPI 1730538281
$6,332.63
in general payments reported to CMS, 2019-2025
28 companies · $969 in 2025
The $969 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $977 · 2022: $2,873 · 2023: $920 · 2024: $593 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,270.81 | 2021-2025 | Proclaim |
| Boston Scientific Corporation | $736.00 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $328.42 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $280.19 | 2022 | |
| Medtronic, INC. | $269.83 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Scilex Pharmaceuticals INC. | $257.42 | 2021-2022 | |
| Spinal Simplicity, LLC | $198.82 | 2022 | |
| Biodelivery Sciences International, INC. | $156.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $132.51 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.96 | 2025 | Caplyta |
| Grt US Holding, INC. | $129.83 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $128.75 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $125.01 | 2024 | Voquezna |
| Vanda Pharmaceuticals INC. | $124.99 | 2024 | Fanapt |
| Dexcom, INC. | $121.83 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $121.83 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2025 | Fasenra |
| Teva Pharmaceuticals USA, INC. | $121.36 | 2021-2022 | |
| Genzyme Corporation | $119.08 | 2025 | |
| Novo Nordisk INC | $104.63 | 2025 | Wegovy |
| Neurocrine Biosciences, INC. | $99.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.94 | 2025 | |
| Amgen INC. | $70.59 | 2021-2022 | |
| Eisai INC. | $33.92 | 2021 | |
| Pacira Therapeutics, INC. | $23.29 | 2021 | |
| Lilly USA, LLC | $19.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.08 | 2021 | |
| Pfizer INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.